BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28502078)

  • 1. Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
    Ito D; Yogosawa S; Mimoto R; Hirooka S; Horiuchi T; Eto K; Yanaga K; Yoshida K
    Cancer Sci; 2017 Aug; 108(8):1565-1573. PubMed ID: 28502078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
    Yan H; Hu K; Wu W; Li Y; Tian H; Chu Z; Koeffler HP; Yin D
    PLoS One; 2016; 11(8):e0159954. PubMed ID: 27532268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enforced dual-specificity tyrosine-regulated kinase 2 expression by adenovirus-mediated gene transfer inhibits tumor growth and metastasis of colorectal cancer.
    Imaizumi Y; Yoshida S; Kanegae Y; Eto K; Yoshida K
    Cancer Sci; 2022 Mar; 113(3):960-970. PubMed ID: 34932844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer.
    Kumamoto T; Yamada K; Yoshida S; Aoki K; Hirooka S; Eto K; Yanaga K; Yoshida K
    Int J Oncol; 2020 Jun; 56(6):1529-1539. PubMed ID: 32236621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4.
    Li Y; Yang Y; Li J; Liu H; Chen F; Li B; Cui B; Liu Y
    Oncotarget; 2017 May; 8(20):32683-32695. PubMed ID: 28427243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
    Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
    Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
    Mimoto R; Taira N; Takahashi H; Yamaguchi T; Okabe M; Uchida K; Miki Y; Yoshida K
    Cancer Lett; 2013 Oct; 339(2):214-25. PubMed ID: 23791882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
    Zhang D; Zhao L; Shen Q; Lv Q; Jin M; Ma H; Nie X; Zheng X; Huang S; Zhou P; Wu G; Zhang T
    Int J Cancer; 2017 May; 140(10):2298-2309. PubMed ID: 28213952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
    Yokoyama-Mashima S; Yogosawa S; Kanegae Y; Hirooka S; Yoshida S; Horiuchi T; Ohashi T; Yanaga K; Saruta M; Oikawa T; Yoshida K
    Cancer Lett; 2019 Jun; 451():100-109. PubMed ID: 30851422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEA15 promotes liver metastasis of colorectal cancer by upregulating the ERK/MAPK signaling pathway.
    Tang B; Liang W; Liao Y; Li Z; Wang Y; Yan C
    Oncol Rep; 2019 Jan; 41(1):43-56. PubMed ID: 30365128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
    Hashimoto M; Kobayashi T; Tashiro H; Arihiro K; Kikuchi A; Ohdan H
    Int J Cancer; 2016 Aug; 139(4):812-23. PubMed ID: 27037526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
    Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
    Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
    Yamashita S; Chujo M; Tokuishi K; Anami K; Miyawaki M; Yamamoto S; Kawahara K
    J Thorac Cardiovasc Surg; 2009 Dec; 138(6):1303-8. PubMed ID: 19818968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer.
    Miyoshi J; Toden S; Yoshida K; Toiyama Y; Alberts SR; Kusunoki M; Sinicrope FA; Goel A
    Sci Rep; 2017 Mar; 7():43393. PubMed ID: 28262692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression.
    Zhang Y; Li KF
    Biomed Pharmacother; 2019 Dec; 120():109127. PubMed ID: 31629952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
    Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
    Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy.
    Nomura S; Suzuki Y; Takahashi R; Terasaki M; Kimata R; Terasaki Y; Hamasaki T; Kimura G; Shimizu A; Kondo Y
    BMC Urol; 2015 Jun; 15():53. PubMed ID: 26087959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
    Gao T; Wang M; Xu L; Wen T; Liu J; An G
    J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
    Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.